Heba M. Ismail
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
199
Citations
1,958
Est. group size
~1
Recurring co-author estimate
Active years
21
Publishing since 2006
Heba M. Ismail studies type 1 diabetes, a condition where the body's immune system attacks the insulin-producing cells of the pancreas. The work focuses on tracking how the disease develops and progresses, using blood-based markers (such as metabolites linked to gut bacteria) and models of pancreatic beta-cell function, and applying tools like machine learning to predict key turning points. Related projects examine gut microbiome influences on metabolic health and biomarkers for detecting infection in newborns.
Publication activity has grown steadily over the last decade, rising from a handful per year to roughly 30 per year in recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Predicting the Timing of the Metabolic Inflection Point in Type 1 Diabetes Progression Using Machine Learning and Survival Analysis Models
Diabetes · 2026
- Impact of Body Size on Preclinical Type 1 Diabetes Development and Progression
Diabetes Care · 2026
- The diagnostic and prognostic values of soluble CD14 subtype (presepsin) in detection of early onset neonatal sepsis in preterm newborns
Journal of Neonatal-Perinatal Medicine · 2026
- Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function
The Journal of Clinical Endocrinology & Metabolism · 2025
- Serum Metabolomics Reveals Potential Differences in Gut Microbiota–Associated Metabolites in Twins Discordant for Type 1 Diabetes
Diabetes · 2025
- Exploring Microbiota-Associated Metabolites in Twins Discordant for Type 1 Diabetes
medRxiv · 2025
- Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals with Type 1 Diabetes
medRxiv · 2025
- Enhancing Recruitment Rate and Heterogeneity in the TrialNet Pathway to Prevention Study: Insights from a Single Center Experience
medRxiv · 2025
- 719-P: Oral Disposition Index (oDI) as an Outcome Measure in Type 1 Diabetes (T1D) Clinical Trials—Evidence from Stage 1 and Stage 2 Trials
Diabetes · 2025
- Soluble CD14 (Presepsin) in the early prediction of bacterial type in Early Onset Neonatal Sepsis in Preterm Neonates
Research Square · 2025
- Experimental <i>Eimeria tenella</i> infection of chickens followed by very virulent infectious bursal disease viral challenge: clinical and pathological effects
Avian Pathology · 2025
- <b>Serum Metabolomics Reveals Potential Differences in Gut</b><b><i> </i></b><b>Microbiota-Associated Metabolites in Twins Discordant for Type 1 Diabetes</b>
2025
- <b>Serum Metabolomics Reveals Potential Differences in Gut</b><b><i> </i></b><b>Microbiota-Associated Metabolites in Twins Discordant for Type 1 Diabetes</b>
2025
- Diagnostic Accuracy of Soluble CD14 (Presepsin) in Identifying Gram- Positive versus Gram-Negative Infections in Preterm Neonates with Early-Onset Sepsis
Research Square · 2025
- Too soon to grow: linking gut health to early puberty onset
Pediatric Research · 2025
- Diabetes×55
- Communications Medicine×16
- Diabetes Care×14
- medRxiv×8
- Diabetologia×6
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile